Greenwich LifeSciences, Inc. GLSI
Greenwich LifeSciences, Inc. (Nasdaq: GLSI) is an oncology drug developer. Its lead program, GLSI-100 (GP2 + GM-CSF), is in Phase 3 for Prevention of breast cancer recurrences in HER2/neu positive patients with residual disease or high-risk pathologic complete response.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| GLSI-100 (GP2 + GM-CSF) | Prevention of breast cancer recurrences in HER2/neu positive patients | vaccine | Phase 3 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.